Event Type: The management/officials of Mankind Pharma Limited will be participating in an Investor Conference organized by Bank of America and subsequent meetings with various investors. The meeting types include Group Meeting and One-on-One/Group Meeting.
Date and Time: The events are scheduled for:
- June 1, 2026: Conference organized by Bank of America (Mumbai)
- June 2, 2026: Meeting with various investors (Mumbai)
Purpose of Event: The participation is for investor conference/event interactions. The company specifically states that during these meetings with investors/analysts, no unpublished price sensitive information (UPSI) shall be disclosed. All discussions will be based on the general business outlook and information already available in the public domain.
Timing Relative to Earnings: The disclosure does not specify whether this meeting is scheduled before or after any earnings announcement.
Management Participants: The document does not specify which particular management members or officials will be participating in these events.
Availability of Materials: The company indicates that no presentation, earnings deck, transcript, or recording will be made available, as the disclosure explicitly states that only publicly available information will be discussed.
UPSI Compliance: The company has clearly indicated that no unpublished price sensitive information (UPSI) will be shared during these meetings. The disclosure specifically states: "During the meeting with investors/analysts no unpublished price sensitive information ('UPSI') shall be disclosed which is not already available in public domain."
Financial Information: No financial highlights, guidance references, or presentation summaries were included in this disclosure. The company explicitly states that discussions will be limited to information already in the public domain.
Additional Notes Section
Attachments: The disclosure does not mention any attachments such as invites, investor decks, conference schedules, or compliance letters being included with this filing.
Financial Data Disclosure: No financial data or figures were disclosed in this announcement. The document serves purely as an intimation of participation in investor events.
Logistical Details: The document does not include dial-in numbers, access codes, or other logistical details for the meetings.
Special Circumstances: The company notes that the participation in the Bank of America investor conference was "finalised at short notice," hence this intimation was submitted accordingly. The schedule is also noted as being "subject to change due to exigencies on either side."
Website Disclosure: The intimation of participation is also being uploaded on the company's website at www.mankindpharma.com.